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A B S T R A C T
Vitamin D insufﬁciency is prevalent in chronic kidney disease (CKD) and associated with secondary
hyperparathyroidism (SHPT) and increased risk of bone and vascular disease. Unfortunately, supplemen-
tationof stage 3or4CKDpatientswith currently recommendedvitaminD2 orD3 regimensdoesnot reliably
restore serum total 25-hydroxyvitamin D to adequacy (30ng/mL) or effectively control SHPT. Preclinical
and clinical studies were conducted to evaluate whether the effectiveness of vitamin D repletion depends,
at least in part, on the rate of repletion. A modiﬁed-release (MR) oral formulation of calcifediol
(25-hydroxyvitamin D3) was developed which raised serum 25-hydroxyvitamin D3 and calcitriol levels
gradually. Singledosesofeitherbolus intravenous (IV)ororalMRcalcifediolwereadministered tovitaminD
deﬁcient rats. Bolus IV calcifediol produced rapid increases in serum 25-hydroxyvitamin D3, calcitriol and
FGF23, along with signiﬁcant induction of CYP24A1 in both kidney and parathyroid gland. In contrast, oral
MR calcifediol produced gradual increases in serum 25-hydroxyvitamin D3 and calcitriol and achieved
similar hormonal exposure, yet neither CYP24A1 nor FGF23 were induced. A 10-fold greater exposure to
bolus IV than oralMR calcifediol was required to similarly lower intact parathyroid hormone (iPTH). Single
doses of oralMR (450 or 900mg) or bolus IV (450mg) calcifediolwere administered to patientswith stage 3
or 4 CKD, SHPT and vitamin D insufﬁciency. Changes in serum 25-hydroxyvitamin D3 and calcitriol and in
plasma iPTH were determined at multiple time-points over the following 42 days. IV calcifediol produced
abrupt andpronounced increases in serum25-hydroxyvitaminD3 and calcitriol, but little change inplasma
iPTH. As in animals, these surges triggered increased vitamin D catabolism, as evidenced by elevated
production of 24,25-dihydroxyvitamin D3. In contrast, MR calcifediol raised serum 25-hydroxyvitamin D3
and calcitriol gradually, and meaningfully lowered plasma iPTH levels. Taken together, these studies
indicate that rapid increases in 25-hydroxyvitamin D3 trigger CYP24A1 and FGF23 induction, limiting
effective exposure to calcitriol and iPTH reduction in SHPT. They also support further investigation of
gradual vitamin D repletion for improved clinical effectiveness.
This article is part of a Special Issue entitled "17th Vitamin D Workshop".
ã 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Vitamin D insufﬁciency is associated with chronic kidney
disease (CKD) and gives rise to secondary hyperparathyroidism
(SHPT) which can lead to loss of bone density and elevated rates of
fracture in renal patients [1]. Vitamin D therapies are therefore
widely used in the management of chronic kidney disease (CKD).
Vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol)
supplementation is the standard of care for correcting vitamin D
insufﬁciency in CKD [2], while vitamin D hormones (calcitriol and
other synthetic hormones) are used to control SHPT [3]. Both of
these therapeutic approaches have signiﬁcant limitations.
Vitamins D2 and D3 (collectively “vitamin D”) are absorbed
less readily than more polar vitamin D compounds [4], and the
degree of absorption can vary considerably between patients [5].
Once absorbed, vitamin D must undergo two sequential hydrox-
ylations to be active: ﬁrst at carbon 25 by CYP2R1 or CYP27A1 to
form25-hydroxyvitaminD, and thenat carbon1byCYP27B1to form
1,25-dihydroxyvitamin D [6]. Hepatic 25-hydroxylation varies
widely in efﬁciency and, together with variable absorption,
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complicates the determination of optimal dose [7,8]. Signiﬁcant
percentagesofCKDpatients receivingvitaminDsupplementsdonot
attain targeted levels of serum 25-hydroxyvitamin D [9,10].
Recommended repletion [11] comprises intermittent high dose
regimenswhichmaytriggeracceleratedvitaminDcatabolism[12].A
comprehensive review of the topic concluded that vitamin D
supplementation is generally ineffective in clinical management of
CKD patients [13].
Vitamin D hormones induce the desired clinical responses in
target tissues, such as increased intestinal calcium uptake and
suppression of iPTH production, by directly activating the vitamin
D receptor [14]. Production of 1,25-dihydroxyvitamin D by renal
CYP27B1 is controlled by feedback inhibition, thereby protecting
tissues from overexposure. However, vitamin D hormone therapy
is not subject to feedback regulation and can readily cause
oversuppression of iPTH, hypercalcemia and hyperphosphatemia,
leading to adynamic bone disease and vascular calciﬁcation [15].
Hormones also accelerate vitamin D catabolism and raise target
tissue resistance by inducing CYP24A1 [16] which can mitigate the
desired therapeutic responses and exacerbate vitamin D insufﬁ-
ciency.
The limitations of current vitamin D supplementation and
hormone replacement therapies have led us to re-examine
calcifediol (25-hydroxyvitamin D3) as a potentially effective
intervention for restoring adequate serum levels of 25-hydrox-
yvitamin D and safely controlling SHPT. Calcifediol is more readily
absorbed than vitamin D [17,18] and requires only 1-hydroxylation
for activation, which remains under physiological feedback
regulation. We investigated whether gradual delivery of calcife-
diol, using a modiﬁed-release (MR) formulation for oral adminis-
tration, would minimize CYP24A1 upregulation, thereby
improving its effectiveness. The nonclinical and clinical studies
described herein compared MR and bolus intravenous (IV)
calcifediol with regard to effects on serum levels of vitamin D
metabolites, plasma iPTH, serum FGF23, and tissue expression of
the catabolic enzyme CYP24A1.
2. Materials, methods and results
2.1. Non-clinical studies
2.1.1. Animals
Adultmale Sprague Dawley rats (6–8weeks of age) fromHilltop
Lab Animals Inc., (Scottdale, PA, USA) were maintained on a
vitamin D deﬁcient diet for 8 weeks after which detectable serum
25-hydroxyvitamin D was negligible. Two groups of twenty-ﬁve
rats were administered a single 0.4mL IV injection of either
calcifediol (4.5mg) or vehicle (30:50:20, v/v/v propylene glycol:
saline:ethanol). Two additional groups of 25 rats were adminis-
tered by gavage hard shell gelatin capsules containing an MR
formulation of calcifediol (4.5mg) or the MR calcifediol formula-
tion alone (comprising a wax matrix). The MR formulation
progressively released calcifediol over a 12-hour period during
in vitro dissolution testing. Serum or plasma were collected post-
dose at 0, 0.08, 0.25, 0.5, 1, 2, 4, 8, 12 and 24h.
2.1.2. Plasma iPTH
Determined with the rat iPTH ELISA kit (Immutopics, San
Clemente, CA, USA).
2.1.3. Serum FGF23
Measured using an FGF23 ELISA kit (Kainos Laboratories, Tokyo,
Japan).
2.1.4. CYP24A1, CYP27B1 and PTH mRNA
Kidney and parathyroid gland tissue samples were excised and
frozen in RNAlater1 and were processed using an automated hard
tissue homogenizer. RNA was isolated using TRIzol1 Reagent
(Invitrogen). The ThermoScriptTM RT-PCR System kit (Invitrogen)
was used to create cDNA from 10mg of RNA. The TaqMan1 probes
speciﬁc for rat Cyp24A1 (Cat. # Rn01423141_g1), Cyp27B1
(Rn00678309_g1), PTH (Rn00566882_m1) and GAPDH
(Rn99999916_s1) were designed and manufactured by Applied
Biosystems Inc., (Foster City, CA). Quantitative real-time PCR was
performed using an ABI Prism 7000 sequence detection system
(Applied Biosystems) using Taqman Universal PCRMasterMix (ABI
#4304437). The relative expression value was calculated by the
comparative CT method using GAPDH as endogenous control. Data
were normalized such that the level of expression in control rats
was equal to 1.0.
2.1.5. Vitamin D metabolites
Serum samples were spiked with [26,27-2H6] 25(OH)D3 or
[25,26-2H6] 1a,25(OH)2D3 to serve as internal standards and
extracted using Accubond II ODS-C18 100mg, 1mL SPE cartridges
(Agilent Technologies, Palo Alto, CA). The collected fractions were
dried under nitrogen, and residues were reconstituted in 50mL of
methanol/H2O (80/20; v/v) and analyzed using LC–MS/MS
[(Fig._1)TD$FIG]
Fig. 1. Effect of bolus IV or oral MR calcifediol administration on serum calcifediol and calcitriol levels in rats. Male rats were maintained on a vitamin D deﬁcient diet for
8 weeks and then divided into 4 treatment groups. Each group received a single 4.5mg dose of bolus IV calcifediol (solid circles) or oral MR calcifediol (solid squares) or the
corresponding vehicles (open circles and squares). Serum levels of calcifediol (A) and calcitriol (B) were measured at the indicated time points post-dose. Error bars indicate
standard deviation (SD). Asterisks denotes signiﬁcant differences between IV and MR treatment groups (P<0.05).
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(Waters Alliance HPLC-Waters Quattro Ultima Mass Spectrometer,
Milford, MA).
2.1.6. Statistical analysis
ANOVA (one- or two-way) and BonferroniMultiple Comparison
post-test were used to determine statistical signiﬁcance set at
p<0.05.
2.2. Results from non-clinical studies
A single bolus IV dose of calcifediol (4.5mg) increased serum
calcifediol levels to approximately 320ng/mL within 5min
(Fig. 1A). Thereafter, calcifediol levels dropped to 110ng/mL by
30min and to 96ng/mL by 24h. A single oral dose of MR calcifediol
(4.5mg) produced a detectable rise in serum calcifediol at 3 h post-
dose, which peaked 2h later at 16ng/mL and dropped to 10ng/mL
by 24h. No changes in serum calcifediol were noted in animals
treated with vehicles.
Bolus IV calcifediol produced a rapid increase in serum calcitriol
frombaseline (whichwas below the limit of quantitation) to 1.1 ng/
mL by 4h (Fig. 1B). Serum calcitriol returned toward baseline by
24h. MR calcifediol produced detectable increases in calcitriol
(>0.1 ng/mL) as early as 1h post-dose and levels rose gradually to
0.6 ng/mL by 24h. No signiﬁcant changes in serum calcium or
phosphorus were observed for either treatment group over the
24-hour post-dose period (data not shown).
Pharmacodynamic changes associated with the observed
increases in serum calcifediol and calcitriol are shown in Fig. 2A
through D. Bolus IV calcifediol rapidly induced
CYP24A1 expression in the kidney which reached a 40-fold
increase by 4–8h post-dose. In contrast, MR calcifediol produced
detectable increases in kidney CYP24A1 expression after 4h which
peaked at only 6-fold above baseline by 12h. No changes in
CYP24A1 expression were observed in vehicle-treated animals.
Serum FGF23 levels increased signiﬁcantly only in animals
receiving bolus IV calcifediol (Fig. 2B) and remained higher 24h
post-dose. Kidney CYP27B1 mRNA transcript levels were rapidly
and completely suppressedwith IV calcifediol treatment by 8h and
remained suppressed at 24h (Fig. 2C). In contrast, neither MR
calcifediol nor vehicle treatment caused signiﬁcant changes in
serum FGF23 or CYP27B1 expression.
A rapid and prominent surge in CYP24A1 expression was
observed in parathyroid gland tissue obtained from animals
treated with bolus IV calcifediol which peaked at 4h post-dose
[(Fig._2)TD$FIG]
Fig. 2. Effect of bolus IV or oralMR calcifediol administration onmediators of vitamin Dmetabolism in rats. Expression of kidney CYP24A1 transcripts (A), serum intact FGF23
(B), kidney CYP27b1 transcripts (C) and parathyroid gland CYP24A1 transcripts (D) weremeasured in vitamin D deﬁcient rats sacriﬁced at the indicated time points following
treatmentwith a single 4.5mg dose of bolus IV calcifediol (solid circles) or oralMR calcifediol (solid squares) or the corresponding IV orMR vehicles (open circles and squares).
Asterisks denote signiﬁcant differences between IV and MR treatment groups (P<0.05).
[(Fig._3)TD$FIG]
Fig. 3. Effect of bolus IV or oralMR calcifediol administration on plasma iPTH levels
in rats. Plasma iPTH levels were determined in vitamin D deﬁcient rats treated with
bolus IV calcifediol (solid circles), MR capsules (solid squares) or the corresponding
MR vehicle capsules (open squares). Baseline iPTH level corresponds to mean iPTH
levels obtained in vehicle control animals over the course of the treatment period.
Data for the IV vehicle were equivalent to the MR vehicle and were omitted for
improved clarity. Both IV andMR iPTH treatment groupswere signiﬁcantly different
from their correspnding vehicle controls at all time points post-treatment as
denoted by asterisks (P<0.05).
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at a level 13-fold higher than baseline (Fig. 2D). In contrast,
parathyroid gland CYP24A1 expression rose more gradually in
animals treated with MR calcifediol, peaking at 12h post-dose at a
level 5-fold higher than baseline. Plasma iPTH was equally
suppressed in both treatment groups at 24h post-dose (Fig. 3).
2.3. Clinical studies
2.3.1. Subjects
Twenty-nine (29) subjects with stage 3 or 4 CKD, SHPT and
vitaminDinsufﬁciency (deﬁnedasserumtotal25-hydroxyvitaminD
below30ng/mL)were randomized tooneof three treatmentgroups.
2.3.2. Treatment
Subjects were orally administered a single oral dose of MR
calcifediol (either 450mg or 900mg) or a single bolus IV injection
of calcifediol (448mg). For the oral doses, 5 or 10 capsules (90mg
each) were administered after an overnight fast with water
(maximum 12ounces) within 15m. The MR capsules used in these
clinical studies were similar to those used in the non-clinical
studies, also comprising a wax matrix to effect the more gradual
release of calcifediol. In vitro dissolution testing showed that the
MR capsules progressively released calcifediol over a 12-hour
period (data not shown). For IV dosing, 0.56mL (448mg) of
calcifediol formulated in propylene glycol:saline:ethanol
(30:50:20, v/v/v), was injected within 1min into a peripheral
vein. The strengths of the dosing formulations were veriﬁed prior
to and after administration.
2.3.3. Sample analysis
Blood samples were collected at 18, 12 and 6h pre-dose to
establish baseline values. For the oral dose groups, post-dose blood
samples were collected at 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, and
48h, and at 4, 7, 14, 21, 28, and 42 days. For the IV group, post-dose
samples were collected at 5,10,15, and 30min, at 1, 2, 4, 6, 8,12, 24,
and 48h, and at 4, 7, 14, 21, 28, and 42 days. Blood samples were
shipped to Spectra Clinical Research (Rockleigh, New Jersey) for all
analyses except determinations of serum calcifediol and 24,25-
dihydroxyvitamin D3, for which samples were forwarded to
inVentiv (Québec, QC, Canada) for analysis by a high performance
liquid chromatographic method with tandem mass spectrometry
detection (HPLC–MS/MS). Spectra determined the level of
1,25-dihydroxyvitamin D in serum using an Immunodiagnostic
Systems Ltd. (IDS) Enzyme Immuno Assay (EIA) kit.
[(Fig._4)TD$FIG]
Fig. 4. Effect of bolus IV or oralMR calcifediol administration on serum levels of calcifediol and 1,25-dihydroxyvitamin D in patients. Patientswith stage 3 or 4 CKD, SHPTand
vitamin D insufﬁciency were treatedwith a single bolus IV injection of 448mg calcifediol (solid circles) or single doses of oralMR calcifediol (450mg–solid triangles; 900mg–
solid squares). Serum samples obtained at the indicated time points were analyzed for (A) calcifediol (25(OH)D3) and (B) 1,25-dihydroxyvitamin D. Data are corrected for
baseline values. Asterisk denotes signiﬁcant differences at all time points post-treatment between IV and MR treatment groups (P<0.05).
286 M. Petkovich et al. / Journal of Steroid Biochemistry & Molecular Biology 148 (2015) 283–289
2.3.4. Statistical analysis
Differences between treatment groups were analyzed by a
one- or two-sided t-test, as appropriate, with statistical signiﬁ-
cance set at p<0.05.
2.4. Results of clinical studies
2.4.1. Serum calcifediol
The effects of single bolus IV versus oral MR administration of
calcifediol on baseline-adjusted serum calcifediol levels are
shown in Fig. 4A for 0–96h. Mean baseline concentrations were
23.7 ng/mL for the 448-mg IV group and 18.3 and 18.7 ng/mL for
the MR 450mg and 900mg groups, respectively. Peak mean
calcifediol concentrations were observed at 0.5 h after bolus IV
dosing versus 13.1 and 13.6 h post-dose for oral MR dosing at
450mg and 900mg, respectively. Exposure to calcifediol, based on
observed area-under-the-curve (AUC) and maximum concentra-
tion (Cmax), was far higher after IV than MR administration: mean
baseline corrected Cmax was 110.3 ng/mL for the IV group and
6.9 and 14.2 ng/mL for the oral MR groups. Exposure was
approximately dose-proportional with the oral MR 450mg and
900mg doses.
2.4.2. Serum 1,25-dihydroxyvitamin D
Mean baseline concentrations of serum1,25-dihydroxyvitamin
D were 19.3, 21.2 and 26.5 pg/mL for the IV (448mg) and MR
(450mg and 900mg) treatment groups, respectively. Mean
baseline-adjusted concentrations over the 96-hour post-dose
period are shown for the three treatment groups in Fig. 4B.
Following bolus IV calcifediol, mean concentration of serum
1,25-dihydroxyvitamin D rapidly increased by up to 13pg/mL at
6 h post-dose. In contrast, mean concentrations in the oral MR
groups gradually increased and peaked at approximately 3 and
7pg/mL over baseline, respectively, by 48h post-dose. The mean
AUC was 7449 and 2530pg.h/mL for the IV (448mg) and MR
(900mg) treatment groups, respectively, and these values did
not differ signiﬁcantly. AUC in the 450mg MR group was
negligible.
[(Fig._5)TD$FIG]
Fig. 5. Effect of bolus IV or oralMR calcifediol administration on plasma iPTH levels in patients. Patients with stage 3 or 4CKD, SHPTand vitamin D insufﬁciency were treated
with a single bolus IV injection of 448mg calcifediol (solid circles) or single doses of oral MR calcifediol (450mg–solid triangles; 900mg–solid squares). Plasma samples
obtained at the indicated time points were analyzed for iPTH. Data are corrected for baseline values. Plasma iPTHwas not determined at 96-hours post-dose. Asterisk denotes
signiﬁcant difference between IV and MR treatment groups at 72h. (P<0.05).
[(Fig._6)TD$FIG]
Fig. 6. Effect of bolus IV or oral MR calcifediol administration on plasma 24,25-dihydroxyvitamin D levels in patients. Patients with stage 3 or 4 CKD, SHPT and vitamin D
insufﬁciency were treated with a single bolus IV injection of 448mg calcifediol (solid circles) or single doses of oral MR calcifediol (450mg–solid triangles; 900mg–solid
squares). Plasma samples obtained at the indicated time points were analyzed for 24,25-dihydroxyvitamin D3 levels. Data are expressed as percent of baseline values.
Asterisks denote signiﬁcant differences between IV and MR treatment groups (P<0.05).
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2.4.3. Plasma iPTH
Baseline levels of plasma iPTHwere 184pg/mL for the IV group,
and 168 and 238pg/mL, respectively, for the MR 450 and 900mg
groups. Mean percent changes in iPTH from baselinewereminimal
over the post-dose period for the bolus IV and lower oral MR dose
groups. However, mean percent reduction in plasma iPTH was
signiﬁcant and sustained for the higher oral MR dose, reaching
approximately 20% between 24 and 72h post-dose (Fig. 5). No
signiﬁcant increases in serum calcium were observed in any
treatment group during the post-dose period (data not shown).
2.4.4. Serum 24,25-dihydroxyvitamin D3
Baseline levels of 24,25-dihydroxyvitamin D3 were 1.13ng/mL
for the IV group, and 0.86 and 0.87ng/mL, respectively, for the MR
450 and 900mg groups. Mean values ﬂuctuated around baseline
for the MR 450mg group and increased approximately 0.2 ng/mL
for the MR 900mg group. Mean values increased more dramati-
cally over the course of the study for the IV group and reached
levels approximately 1.0 ng/mL over baseline by two weeks post-
dose, remaining at this level to the end of the study (Fig. 6).
3. Conclusions
Numerous non-clinical and clinical studies have investigated
the therapeutic potential of vitamin D supplementation to control
SHPT and manage metabolic bone disease in CKD patients [19].
Although there is general consensus that vitamin D repletion has
an important role in treating these patients, the body of published
literature shows that supplementation with cholecalciferol or
ergocalciferol is generally unreliable in correcting vitamin D
insufﬁciency and ineffective in controlling SHPT [10,13,20].
Further, there is no consistent view regarding how vitamin D
supplements should best be administered. Published studies have
used daily doses of from 700 to 4000 IU/day, weekly doses of
5000 to 50,000 IU, and monthly doses of 50,000 to 300,000 IU.
The impact of rate of administration on effectiveness of vitamin
D therapies has been poorly investigated. In this paper, we present
results from parallel studies in which calcifediol was delivered
either rapidly as an IV bolus, or gradually via an oral MR
formulation, to vitamin D deﬁcient rats or patients with stage 3
or 4 CKD, SHPT and vitamin D insufﬁciency. Our ﬁndings suggest
that rate of delivery is an important determinant of vitamin D
hormone production, and therefore of therapeutic efﬁcacy, and
that gradual delivery allows more effective treatment of both
vitamin D insufﬁciency and SHPT in CKD patients.
In the presented studies, bolus IV calcifediol produced rapidly
rising and higher drug exposures than oral MR calcifediol, due to a
substantially faster calcifediol release rate and higher bioavailabil-
ity. IV dosing also caused abrupt, large increases in serum
1,25-dihydroxyvitamin D. In vitamin D deﬁcient rats, IV dosing
triggered high expression of CYP24A1 and, subsequently, FGF23,
then near-complete suppression of CYP27B1 and signiﬁcant iPTH
lowering. MR calcifediol yielded equivalent iPTH suppression by
gradually elevating drug exposure and had no dramatic impact on
serum 1,25-dihydroxyvitamin D, serum FGF23, CYP24A1 and
CYP27B1. The gradual increase of CYP24A1 expression in the MR
treated animals is likely due to the gradual restoration of vitamin D
status in these animals. In CKD patients, IV administration yielded
higher serum 24,25-dihydroxyvitamin D3 levels, consistent with
greater CYP24A1 activity, but negligible PTH suppression. Con-
versely, MR administration gradually raised serum calcifediol and
1,25-dihydroxyvitamin D without signiﬁcantly elevating serum
24,25-dihydroxyvitamin D, and produced meaningful, sustained
iPTH suppression.
Data from these studies indicate that renal production of
calcitriol is driven by the supply of calcifediol until CYP27B1 is
suppressed. The faster calcifediol is supplied, the more calcitriol is
produced initially. The abrupt increase in serum calcifediol after
bolus IV dosing produced a corresponding surge in serum calcitriol,
which in turn triggered upregulation of CYP24A1 in both kidney
and parathyroid gland. Increased expression of CYP24A1 appears
to have attenuated the further rise of serum calcitriol (serum
1,24,25-trihydroxyvitamin D3 was not measured) and, after
suppression of renal CYP27B1, drove serum calcitriol in the rats
back to baseline levels at 24h post-dose. In contrast, MR dosing
gradually increased both serum calcifediol and calcitriol, yielding
calcitriol exposures that were greater in the rats and nearly
equivalent in patients.
In rats, the strong upregulation of CYP24A1 by bolus IV
dosing appeared to have been triggered both by the rapid
increase in calcitriol levels and the signiﬁcant elevation of
FGF23 expression. These same factors may have also caused the
almost complete and sustained suppression of renal CYP27B1.
Although, at the end of the treatment period, serum calcitriol
returned to baseline levels, FGF23 remained elevated. We do
not presently know the mechanism sustaining FGF23 levels;
however, this would likely continue to suppress
CYP27B1 expression and maintain CYP24A1 elevation. This
FGF23 “memory” effect would be expected to have an impact
on the efﬁcacy of subsequent dosing, further supporting gradual
repletion over bolus treatments.
Previous studies have demonstrated that increased expression
of CYP24A1 in kidney and extra-renal target tissues is
differentially regulated following increased calcitriol production
[21–23]. This differential regulation may depend on whether
the target tissue in question can respond to FGF23 and
whether FGF23 levels have been increased by vitamin D
treatment.
The observed PTH lowering in rats was equivalent at 24h
post-dose after both IV andMR dosing. However, we postulate that
PTH suppression would not have been sustained for much longer
after IV dosing because CYP24A1was increased in both kidney and
parathyroid gland, serum FGF23 was elevated and CYP27B1 was
suppressed. This is supported by the greater and more sustained
PTH suppression observed in CKD patients between 24 and 72h
after the 900mg MR dose.
Bolus IV administration of calcifediol induced a 40-fold surge in
kidney CYP24A1 expression by 4–8h post-dose. This rapid
induction of CYP24A1 was similar to that observed previously in
rats (46-fold increase in kidney and 25-fold increase in intestine)
following 2.5 weeks of high-dose vitamin D (three treatments per
week of 25,000 IU each) [23]. This previous study demonstrated
that consecutive rapid administrations of vitamin D progressively
raised CYP24A1 levels, attenuating the intended impact of
treatment. Recent clinical studies have shown that treatment
of CKD patients with bolus cholecalciferol results in a shift of
vitamin D balance to net degradationwith increased production of
24,25-dihydroxyvitamin D3, reduced production of 1,25-dihydrox-
yvitamin D and increased FGF23 expression [24]. Consistent with
our ﬁndings, bolus cholecalciferol was not effective at suppressing
iPTH. In our study, patients receiving bolus calcifediol exhibited
elevated and sustained production of 24,25-dihydroxyvitamin D3.
This likely reﬂects elevated CYP24A1 expression both in the kidney
as well as in other vitamin D target tissues, but the mechanism
underlying continued production of 24,25-dihydroxyvitamin D3
over 42 days is unknown.
It is notable that both rat and patient responses to different
rates of calcifediol administration were similar. This supports the
use of the model to further investigate mechanisms affecting the
efﬁcacies of different vitamin D repletion regimens including
comparisons between oral IR and MR formulations both in single-
dose and repeat dose studies.
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Takentogether, thestudiespresentedherein indicate thattherate
at which vitamin D therapy is administered can have a signiﬁcant
impact on treatment outcomes. Further, they support continued
investigationofMRcalcifediolasatreatmentofSHPTinpatientswith
CKD and vitamin D insufﬁciency.
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